Retrospective study about the application of neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced epithelial ovarian cancer.

Retrospective study about the application of neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced epithelial ovarian cancer. - GOTIC019

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036816

Enrollment

1500

Registered

2019-05-22

Start date

2019-01-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epithelial ovarian cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Woman with FIGO stage III/IV epithelial ovarian, Fallopian tube, or primary peritoneal cancer who initiated therapy between January 1, 2010 and December 31, 2015. 2. Woman with malignant tumor confirmed by cytology or histology. 3. Woman who received 3 or more cycles of first-line chemotherapy.

Exclusion criteria

Exclusion criteria: 1. Woman with tumor including component of mesenchymal malignant tumor. 2. Woman with borderline tumor.

Design outcomes

Primary

Measure	Time frame
The factors to select the most appropriate therapy (primary surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery).	—

Secondary

Measure	Time frame
The cross-sectional data of neoadjuvant chemotherapy (NAC) followed by interval debulking surgery. The most appropriate NAC regimen. The most appropriate cycle number of NAC. The most appropriate timing of interval debulking surgery. The goal of interval debulking surgery.	—

Countries

Japan

Contacts

Public ContactShoji Nagao

Hyogo Cancer Center Gynecologic Oncology

nagao@hp.pref.hyogo.jp078-929-1151

Outcome results